Approval · Notice of Compliance 15871 · 2014
ESBRIET: Notice of Compliance 15871
Issued July 10, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15871
- Date
- July 10, 2014
- Company
- Intermune Canada Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide new information regarding drug drug interaction between pirfenidone and cyp1a2 inhibitors
- Therapeutic class
- Anti-fibrotic / anti-inflammatory agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESBRIET | Not yet assigned | — |
Medicinal ingredients
- PIRFENIDONE 267 MG per CAP